Author: Danny Sullivan |  Published on: August 26, 2025  |  Last updated: August 26, 2025

Life Biosciences has presented promising new preclinical data showing that their approach of partial epigenetic reprogramming can positively impact multiple organ systems, beyond just the eye. Their two main programs, ER-100 for optic neuropathies and ER-300 for liver disease, use three Yamanaka factors to reset the epigenetic landscape of aged or damaged cells.

Key points for a public persona blog:

• Life Biosciences demonstrated that their therapy improved various markers of liver health in a mouse model of metabolic dysfunction-associated steatohepatitis (MASH), a condition affecting about 5% of people and increasing risks of cirrhosis and liver cancer.

• The liver therapy (ER-300) reduced liver enzymes, cholesterol, bile acids, and signs of liver fat accumulation and steatosis independently of body weight changes, suggesting a direct effect on liver cells.

• Their epigenetic reprogramming technology, initially developed for neurons in the eye, showed it can “transcend organs” and work in very different tissues like the liver, highlighting the broad potential of this approach for multiple age-related diseases.

• For optic neuropathies, the ER-100 program restored DNA methylation patterns associated with neuronal regeneration, showing targeted gene effects related to nervous system development and neurogenesis.

• The company plans to file for clinical trials of ER-100 in eye diseases by the end of 2025 and expects to start human trials in early 2026.

• Liver health is a strategic focus due to its critical impact on overall health and longevity, and though still in discovery, ER-300 shows strong potential as a second clinical program.

This data reinforces the exciting possibility that partial epigenetic reprogramming can be a versatile therapeutic strategy to address aging and disease across multiple organs, expanding the horizon for regenerative and longevity medicine.